ClinicalTrials.gg

Program

vicadrostat

Also written as “BI 690517”, “Vicadrostat” and “Vicadrostat + empagliflozin”.

In Boehringer Ingelheim's pipeline, Aldosterone synthase inhibitor / SGLT2 inhibitor. Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus, Type 2 · Diabetic Nephropathies · Liver Diseases, led by Boehringer Ingelheim.

Furthest: phase 3, since May 10, 202416 company-led studies, 5 open or runningNext primary completion: Dec 11, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim165 open or runningphase 3since May 10, 2024Sep 1, 2016Dec 11, 2026phase 1 · NCT07845630
  • Named in Boehringer Ingelheim’s own pipeline as Vicadrostat (BI 690517), phase 3, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 1, 2016.

  1. Jun 30, 2017Phase 1 study in HealthyNCT03206632 · 56 enrolled · Korea, Republic of
  2. Jul 20, 2018Phase 1 study in HealthyNCT03608072 · 36 enrolled · Japan
  3. Jan 5, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05182840 · 714 enrolled · United States, Argentina, Australia and more
  4. Aug 24, 2022Phase 1 study in HealthyNCT05515588 · 14 enrolled · Netherlands
  5. Feb 8, 2023Phase 1 study in Liver DiseasesNCT05731908 · 28 enrolled · United States
  6. May 10, 2024Phase 3 study in Heart FailureNCT06424288 · 6,712 planned · United States, Argentina, Australia and more
  7. Jul 29, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06531824 · 8,371 enrolled · United States, Argentina, Australia and more
  8. Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06926660 · 492 enrolled · United States, Argentina, Australia and more
  9. Apr 17, 2025Phase 3 study in Heart FailureNCT06935370 · 4,200 planned · United States, Argentina, Belgium and more
  10. Jun 17, 2025Phase 1 study in HealthyNCT07035457 · 15 enrolled · Germany
  11. Jul 11, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07064473 · 11,800 planned · United States, Argentina, Australia and more
  12. Aug 19, 2025Phase 1 study in HealthyNCT07133399 · 32 enrolled · Germany
  13. Apr 1, 2026Phase 1 study in HealthyNCT07513207 · 45 enrolled · Germany
  14. Sep 23, 2026Phase 1 study in HealthyNCT07845630 · 36 planned · Germany

Ahead

  1. Dec 11, 2026Primary completion: phase 1 study in HealthyNCT07845630
  2. Dec 31, 2026Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06531824
  3. May 22, 2028Primary completion: phase 3 study in Heart FailureNCT06424288
  4. Feb 4, 2029Primary completion: phase 3 study in Heart FailureNCT06935370

TargetBeta

“Aldosterone synthase inhibitor / SGLT2 inhibitor”the company's pipeline, read by Claude · source

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07845630Healthy · Germany1RecruitingDec 11, 202636
NCT07513207Healthy · Germany1CompletedJul 24, 202645
NCT07133399Healthy · Germany1CompletedOct 22, 202532
NCT07064473Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3RecruitingDec 14, 202911,800
NCT07035457Healthy · Germany1CompletedAug 7, 202515
NCT06935370Heart Failure · United States, Argentina, Belgium and more3RecruitingFeb 4, 20294,200
NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedAug 14, 2026492
NCT06531824Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingDec 31, 20268,371
NCT06424288Heart Failure · United States, Argentina, Australia and more3RecruitingMay 22, 20286,712
NCT05731908Liver Diseases · United States1CompletedApr 13, 202328
NCT05515588Healthy · Netherlands1CompletedNov 17, 202214
NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedJun 19, 2023714
NCT03608072Healthy · Japan1CompletedJan 31, 201936
NCT03206632Healthy · Korea, Republic of1CompletedOct 13, 201756
NCT03165240Diabetic Nephropathies · Denmark, France, Germany and more1CompletedApr 16, 202062
NCT02891148Healthy · Germany1CompletedDec 12, 201650

How it is read

Names in the registry

  • “BI 690517”, 8 entries
  • “Vicadrostat”, 5 entries
  • “vicadrostat”, 2 entries
  • “Vicadrostat + empagliflozin”, 1 entry
  • “vicadrostat / empagliflozin combination 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.